Cargando…

Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort

OBJECTIVES: Predicting the presence or absence of coronary artery disease (CAD) is clinically important. Pretest probability (PTP) and CAD consortium clinical (CAD2) model and risk scores used in the guidelines are not sufficiently accurate as the only guidance for applying invasive testing or disch...

Descripción completa

Detalles Bibliográficos
Autores principales: Eurlings, Casper G M J, Bektas, Sema, Sanders-van Wijk, Sandra, Tsirkin, Andrew, Vasilchenko, Vasily, Meex, Steven J R, Failer, Michael, Oehri, Caroline, Ruff, Peter, Zellweger, Michael J, Brunner-La Rocca, Hans-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516207/
https://www.ncbi.nlm.nih.gov/pubmed/36167368
http://dx.doi.org/10.1136/bmjopen-2021-055170
_version_ 1784798658114355200
author Eurlings, Casper G M J
Bektas, Sema
Sanders-van Wijk, Sandra
Tsirkin, Andrew
Vasilchenko, Vasily
Meex, Steven J R
Failer, Michael
Oehri, Caroline
Ruff, Peter
Zellweger, Michael J
Brunner-La Rocca, Hans-Peter
author_facet Eurlings, Casper G M J
Bektas, Sema
Sanders-van Wijk, Sandra
Tsirkin, Andrew
Vasilchenko, Vasily
Meex, Steven J R
Failer, Michael
Oehri, Caroline
Ruff, Peter
Zellweger, Michael J
Brunner-La Rocca, Hans-Peter
author_sort Eurlings, Casper G M J
collection PubMed
description OBJECTIVES: Predicting the presence or absence of coronary artery disease (CAD) is clinically important. Pretest probability (PTP) and CAD consortium clinical (CAD2) model and risk scores used in the guidelines are not sufficiently accurate as the only guidance for applying invasive testing or discharging a patient. Artificial intelligence without the need of additional non-invasive testing is not yet used in this context, as previous results of the model are promising, but available in high-risk population only. Still, validation in low-risk patients, which is clinically most relevant, is lacking. DESIGN: Retrospective cohort study. SETTING: Secondary outpatient clinic care in one Dutch academic hospital. PARTICIPANTS: We included 696 patients referred from primary care for further testing regarding the presence or absence of CAD. The results were compared with PTP and CAD2 using receiver operating characteristic (ROC) curves (area under the curve (AUC)). CAD was defined by a coronary stenosis >50% in at least one coronary vessel in invasive coronary or CT angiography, or having a coronary event within 6 months. OUTCOME MEASURES: The first cohort validating the memetic pattern-based algorithm (MPA) model developed in two high-risk populations in a low-risk to intermediate-risk cohort to improve risk stratification for non-invasive diagnosis of the presence or absence of CAD. RESULTS: The population contained 49% male, average age was 65.6±12.6 years. 16.2% had CAD. The AUCs of the MPA model, the PTP and the CAD2 were 0.87, 0.80, and 0.82, respectively. Applying the MPA model resulted in possible discharge of 67.7% of the patients with an acceptable CAD rate of 4.2%. CONCLUSIONS: In this low-risk to intermediate-risk population, the MPA model provides a good risk stratification of presence or absence of CAD with a better ROC compared with traditional risk scores. The results are promising but need prospective confirmation.
format Online
Article
Text
id pubmed-9516207
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-95162072022-09-29 Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort Eurlings, Casper G M J Bektas, Sema Sanders-van Wijk, Sandra Tsirkin, Andrew Vasilchenko, Vasily Meex, Steven J R Failer, Michael Oehri, Caroline Ruff, Peter Zellweger, Michael J Brunner-La Rocca, Hans-Peter BMJ Open Cardiovascular Medicine OBJECTIVES: Predicting the presence or absence of coronary artery disease (CAD) is clinically important. Pretest probability (PTP) and CAD consortium clinical (CAD2) model and risk scores used in the guidelines are not sufficiently accurate as the only guidance for applying invasive testing or discharging a patient. Artificial intelligence without the need of additional non-invasive testing is not yet used in this context, as previous results of the model are promising, but available in high-risk population only. Still, validation in low-risk patients, which is clinically most relevant, is lacking. DESIGN: Retrospective cohort study. SETTING: Secondary outpatient clinic care in one Dutch academic hospital. PARTICIPANTS: We included 696 patients referred from primary care for further testing regarding the presence or absence of CAD. The results were compared with PTP and CAD2 using receiver operating characteristic (ROC) curves (area under the curve (AUC)). CAD was defined by a coronary stenosis >50% in at least one coronary vessel in invasive coronary or CT angiography, or having a coronary event within 6 months. OUTCOME MEASURES: The first cohort validating the memetic pattern-based algorithm (MPA) model developed in two high-risk populations in a low-risk to intermediate-risk cohort to improve risk stratification for non-invasive diagnosis of the presence or absence of CAD. RESULTS: The population contained 49% male, average age was 65.6±12.6 years. 16.2% had CAD. The AUCs of the MPA model, the PTP and the CAD2 were 0.87, 0.80, and 0.82, respectively. Applying the MPA model resulted in possible discharge of 67.7% of the patients with an acceptable CAD rate of 4.2%. CONCLUSIONS: In this low-risk to intermediate-risk population, the MPA model provides a good risk stratification of presence or absence of CAD with a better ROC compared with traditional risk scores. The results are promising but need prospective confirmation. BMJ Publishing Group 2022-09-26 /pmc/articles/PMC9516207/ /pubmed/36167368 http://dx.doi.org/10.1136/bmjopen-2021-055170 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Cardiovascular Medicine
Eurlings, Casper G M J
Bektas, Sema
Sanders-van Wijk, Sandra
Tsirkin, Andrew
Vasilchenko, Vasily
Meex, Steven J R
Failer, Michael
Oehri, Caroline
Ruff, Peter
Zellweger, Michael J
Brunner-La Rocca, Hans-Peter
Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort
title Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort
title_full Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort
title_fullStr Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort
title_full_unstemmed Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort
title_short Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort
title_sort use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516207/
https://www.ncbi.nlm.nih.gov/pubmed/36167368
http://dx.doi.org/10.1136/bmjopen-2021-055170
work_keys_str_mv AT eurlingscaspergmj useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort
AT bektassema useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort
AT sandersvanwijksandra useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort
AT tsirkinandrew useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort
AT vasilchenkovasily useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort
AT meexstevenjr useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort
AT failermichael useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort
AT oehricaroline useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort
AT ruffpeter useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort
AT zellwegermichaelj useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort
AT brunnerlaroccahanspeter useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort